Tiziana Life Sciences (NASDAQ:TLSA) Stock Makes a Big Move: But Why?

September 3, 2021

Clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, Precision BioSciences along with its ARCUS genome editing platform, and Tiziana Life Sciences (NASDAQ:TLSA) announced on September 2, 2021, a specific license agreement for exploring Tiziana’sforalumab, a completely human anti-CD3 monoclonal antibody for inducing tolerance to improve the clinical outcome of CAR T cell therapy.  Alan List, M.D., Chief Medical Officer at Precision BioSciences, said that the firm…


Tiziana Life Sciences PLC (NASDAQ:TLSA) Stock Falls 11% in a Week

August 12, 2021

Over the course of the past week there has been no news at all about Tiziana Life Sciences PLC (NASDAQ:TLSA), however, the company’s stock has had a rough time and has tanked by as much as 11% during the period. Considering the fact that there has been no news about the company in recent months, it might be right time for investors to take a look at the last major…